Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease

Progress in Retinal and Eye Research

Volumn 31, Issue 3, 2012, Pages 271-285

  Barabino, Stefano ^a   Chen, Yihe ^b   Chauhan, Sunil ^b   Dana, Reza ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Anti inflammatory agents; Autoimmunity; Dry eye disease; Inflammation; Ocular surface

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; DOXYCYCLINE; METHYLPREDNISOLONE; MINOCYCLINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TETRACYCLINE; VASCULOTROPIN RECEPTOR 3;

ANTIGEN PRESENTING CELL; CONJUNCTIVA EPITHELIUM; CORNEA EPITHELIUM; DRUG HALF LIFE; DRUG MECHANISM; DRY EYE; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; LACRIMAL GLAND; MEIBOMIAN GLAND; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TEAR FILM;

AFFERENT PATHWAYS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; CHEMOKINES; CORNEA; CYTOKINES; DRY EYE SYNDROMES; EFFERENT PATHWAYS; HOMEOSTASIS; HUMANS; T-LYMPHOCYTES;

EID: 84862827532     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2012.02.003     Document Type: Review

References (177)

1. Abelson M.B., Heller W., Shapiro A.M., Si E., Hsu P., Bowman L.M., AzaSite Clinical Study Group Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am. J. Ophthalmol. 2008, 145:959-965.
2. Ambati B.K., Patterson E., Jani P., Jenkins C., Higgins E., Singh N., Suthar T., Vira N., Smith K., Caldwell R. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br. J. Ophthalmol. 2007, 91:505-508.
3. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., St Leger J., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., De Falco S., Witta J., Baffi J.Z., Raisler B.J., Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
4. Amin A.R., Attur M.G., Thakker G.D., Patel P.D., Vyas P.R., Patel R.N., Patel I.R., Abramson S.B. A novel mechanism of action of tetracyclines: effects on nitric oxide syntheses. Proc. Natl. Acad. Sci. USA 1996, 93:14014-14019.
5. Aragona P., Bucolo C., Spinella R., Giuffrida S., Ferreri G. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients. Invest. Ophthalmol. Vis. Sci. 2005, 46:4474-4479.
6. Barabino S., Rolando M., Camicione P., Ravera G., Zanardi S., Giuffrida S., Calabria G. Systemic linoleic and γ-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003, 22:97-101.
7. Barabino S., Shen L., Chen L., Rashid S., Rolando M., Dana M.R. The controlled environment chamber: a new mouse model for dry eyes. Invest. Ophthalmol. Vis. Sci. 2005, 46:2766-2771.
8. Barabino S., Dana M.R. Dry eye syndromes. Chem. Immunol. Allergy 2007, 92:176-184.
9. Barabino S., Montaldo E., Solignani F., Valente C., Mingari M.C., Rolando M. Immune response in the conjunctival epithelium of patients with dry eye. Exp. Eye Res. 2010, 91:524-529.
10. Battat L., Macri A., Dursun D., Pflugfelder S.C. Effects of laser in-situ keratomileusis on tear production, clearance and the ocular surface. Ophthalmology 2001, 108:1230-1235.
11. Baudouin C., Labbè A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Ret. Eye Res. 2010, 29:312-334.
12. Buchholz P., Steeds C.S., Stern L.S., Wiederkehr D.P., Doyle J.J., Katz L.M., Figueiredo F.C. Utility assessment to measure the impact of dry eye disease. Ocul. Surf. 2006, 4:155-161.
13. Cavet M.E., Harrington K.L., Ward K.W., Zhang J.Z. Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells. Mol. Vis. 2010, 16:1791-1800.
14. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., Lederman S., Colonna M., Cortesini R., Dalla-Favera R., Suciu-Foca N. Tolerization of dendritic cells by T (S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 2002, 3:237-243.
15. Chauhan S.K., El Annan J., Ecoiffier T., Goyal S., Zhang Q., Saban D.R., Dana R. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J. Immunol. 2009, 182:1247-1252.
16. Chauhan S.K., Jin Y., Goyal S., Lee H.S., Fuchsluger T.A., Lee H.K., Dana R. A novel pro-lymphangiogenic function for Th17/IL17. Blood 2011, 118:4630-4634. 21908425.
17. Chen Y., Chauhan S.K., Saban D.R., Sadrai Z., Okanobo A., Dana R. Interferon-γ-secreting NK cells promote induction of dry eye disease. J. Leukoc. Biol. 2011, 89:965-972.
18. Corcoran M.P., Meydani M., Lichtenstein A.H., Schaefer E.J., Dillard A., Lamon-Fava S. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J. Endocrinol. 2010, 206:217-224.
19. + regulatory T cells in multiple sclerosis. Ann. Neurol. 2010, 67:625-638.
20. + regulatory thymocytes. Blood 2003, 102:4107-4114.
21. Cursiefen C., Masli S., Ng T.F., Dana M.R., Bornstein P., Lawler J., Streilein J.W. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest. Ophthalmol. Vis. Sci. 2004, 45:1117-1124.
22. Cursiefen C., Chen L., Saint-Geniez M., Hamrah P., Jin Y., Rashid S., Pytowski B., Persaud K., Wu Y., Streilein J.W., Dana R. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc. Natl. Acad. Sci. U.S.A 2006, 103:1405-1410.
23. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem. Immunol. Allergy 2007, 92:50-57.
24. Cursiefen C., Maruyama K., Bock F., Saban D., Sadrai Z., Lawler J., Dana R., Masli S. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J. Exp. Med. 2011, 208:1083-1092.
25. De Paiva C.S., Corrales R.M., Villarreal A.L., Farley W.J., Li D.Q., Stern M.E., Pflugfelder S.C. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res. 2006, 83:526-535.
26. De Paiva C.S., Corrales R.M., Villarreal A.L., Farley W.J., Li D.Q., Stern M.E., Pflugfelder S.C. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest. Ophthalmol. Vis. Sci. 2006, 47:2847-2856.
27. De Paiva C.S., Villarreal A.L., Corrales R.M., Rahman H.T., Chang V.Y., Farley W.J., Stern M.E., Niederkorn J.Y., Li D.Q., Pflugfelder S.C. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest. Ophthalmol. Vis. Sci. 2007, 48:2553-2560.
28. De Paiva C.S., Chotikavanich S., Pangelinan S.B., Pitcher J.D., Fang B., Zheng X., Ma P., Farley W.J., Siemasko K.F., Niederkorn J.Y., Stern M.E., Li D.Q., Pflugfelder S.C. IL-17 disrupts corneal barrier following desiccating stress. Mucosal. Immunol. 2009, 2:243-253.
29. Donnenfeld E., Pflugfelder S.C. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv. Ophthalmol. 2009, 54:321-338.
30. Dreizen N.G., Whitsett C.F., Stulting R.D. Modulation of HLA antigen expression on corneal epithelial and stromal cells. Invest. Ophthalmol. Vis. Sci. 1988, 29:933-939.
31. Dursun D., Kim M.C., Solomon A., Pflugfelder S.C. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am. J. Ophthalmol. 2001, 132:8-13.
32. Ecoiffier T., El Annan J., Rashid S., Schaumberg D., Dana R. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease. Arch. Ophthalmol. 2008, 126:1695-1699.
33. El Annan J., Chauhan S.K., Ecoiffier T., Zhang Q., Saban D.R., Dana R. Characterization of effector T cells in dry eye disease. Invest. Ophthalmol. Vis. Sci. 2009, 50:3802-3807.
34. El Annan J., Goyal S., Zhang Q., Freeman G.J., Sharpe A.H., Dana R. Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. Invest. Ophthalmol. Vis. Sci. 2010, 51:3418-3423.
35. Ellenberg D., Azar D.T., Hallak J.A., Tobaigy F., Han K.Y., Jain S., Zhou Z., Chang J.H. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog. Retin. Eye Res. 2010, 29:208-248.
36. + T cells. J. Immunol. 2005, 175:7093-7097.
37. Enríquez-de-Salamanca A., Castellanos E., Stern M.E., Fernández I., Carreño E., García-Vázquez C., Herreras J.M., Calonge M. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol. Vis. 2010, 16:862-873.
38. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrn M.C., Horton H.F., Fouser L., Carter L., Ling V., Bowman M.R., Carreno B.M., Collins M., Wood C.R., Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000, 192:1027-1034.
39. Frucht-Pery J., Sagi E., Hemo I., Ever-Hadani P. Efficacy of doxycycline and tetracycline in ocular rosacea. Am. J. Ophthalmol. 1993, 116:88-92.
40. Gao J., Morgan G., Tieu D., Schwalb T.A., Luo J.Y., Wheeler L.A., Stern M.E. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp. Eye Res. 2004, 78:823-835.
41. Gayton J.L. Etiology, prevalence, and treatment of dry eye disease. Clin. Ophthalmol. 2009, 3:405-412.
42. Govek S.P., Oshiro G., Anzola J.V., Beauregard C., Chen J., Coyle A.R., Gamache D.A., Hellberg M.R., Hsien J.N., Lerch J.M., Liao J.C., Malecha J.W., Staszewski L.M., Thomas D.J., Yanni J.M., Noble S.A., Shiau A.K. Water-soluble PDE4 inhibitors for the treatment of dry eye. Bioorg. Med. Chem. Lett. 2010, 20:2928-2932.
43. Goyal S., Chauhan S.K., Zhang Q., Dana R. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch. Ophthalmol. 2009, 127:882-887.
44. Goya S., Chauhan S.K., El Annan J., Nallasamy N., Zhang Q., Dana R. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Arch. Ophthalmol. 2010, 128:819-824.
45. Goyal S., Chauhan S.K., Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch. Ophthalmol. 2011 Sep 12, [Epub ahead of print].
46. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
47. Guaschino S., Grimaldi E., Sartore A., Mugittu R., Mangino F., Bortoli P., Pensiero S., Vinciguerra A., Perissutti P. Visual function in menopause: the role of hormone replacement therapy. Menopause 2003, 10:53-57.
48. Gulati A., Sacchetti M., Bonini S., Dana R. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch. Ophthalmol. 2006, 124:710-716.
49. Gupta A., Monroy D., Ji Z., Yoshino K., Huang A., Pflugfelder S.C. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr. Eye Res. 1996, 15:605-614.
50. Hamrah P., Zhang Q., Liu Y., Dana M.R. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest. Ophthalmol. Vis. Sci. 2002, 43:639-646.
51. Hamrah P., Liu Y., Zhang Q., Dana M.R. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:581-589.
52. Hamrah P., Liu Y., Zhang Q., Dana M.R. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. Arch. Ophthalmol. 2003, 121:1132-1140.
53. Hamrah P., Yamagami S., Liu Y., Zhang Q., Vora S.S., Lu B., Gerard C.J., Dana M.R. Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival. Invest. Ophthalmol. Vis. Sci. 2007, 48:1228-1236.
54. Hanemaaijer R., Sorsa T., Konttinen Y.T., Ding Y., Sutinen M., Visser H., van Hinsbergh V.W., Helaakoski T., Kainulainen T., Rönkä H., Tschesche H., Salo T. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J. Biol. Chem. 1997, 272:31504-31509.
55. Hannum C.H., Wilcox C.J., Arend W.P., Joslin F.G., Dripps D.J., Heimdal P.L., Armes L.G., Sommer A., Eisenberg S.P., Thompson R.C. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340.
56. Haque R.M., Torkildsen G.L., Brubaker K., Zink R.C., Kowalski R.P., Mah F.S., Pflugfelder S.C. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea 2010, 29:871-877.
57. Hattori T., Chauhan S.K., Lee H., Ueno H., Dana R., Kaplan D.H., Saban D.R. Characterization of Langerin-expressing dendritic cell subsets in the normal cornea. Invest. Ophthalmol. Vis. Sci. 2011, 52:4598-4604.
58. Hayashi Y., Ishimaru N., Arakaki R., Tsukumo S., Fukui H., Kishihara K., Shiota H., Yasutomo K., Hayashi Y. Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum. 2004, 50:2903-2910.
59. Heur M., Chaurasia S.S., Wilson S.E. Expression of interleukin-1 receptor antagonist in human cornea. Exp. Eye Res. 2009, 88:992-994.
60. Hirota K., Yoshitomi H., Hashimoto M., Maeda S., Teradaira S., Sugimoto N., Yamaguchi T., Nomura T., Ito H., Nakamura T., Sakaguchi N., Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J. Exp. Med. 2007, 204:2803-2812.
61. Hiscott P., Seitz B., Schlötzer-Schrehardt U., Naumann G.O. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res. 1997, 289:307-310.
62. Hoyng P.F., Verbey N., Thörig L., van Haeringen N.J. Topical prostaglandins inhibit trauma induced inflammation in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1986, 27:1217-1225.
63. Horrobin D.F. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scand. J. Rheumatol. 1986, S61:242-245.
64. Huehn J., Hamann A. Homing to suppress: address codes for Treg migration. Trends Immunol. 2005, 26:632-636.
65. Iwata M., Kiritoshi A., Roat M.I., Yagihashi A., Thoft R.A. Regulation of HLA class II antigen expression on cultured corneal epithelium by interferon-gamma. Invest. Ophthalmol. Vis. Sci. 1992, 33:2714-2721.
66. Jayarapu K., Kerr M.S., Katschke A., Johnson R.M. Chlamydia muridarum-specific CD4 T-cell clones recognize infected reproductive tract epithelial cells in an interferon-dependent fashion. Infect. Immun. 2009, 77:4469-4479.
67. Jiang G., Ke Y., Sun D., Li H., Ihnen M., Jumblatt M.M., Foulks G., Wang Y., Bian Y., Kaplan H.J., Shao H. A new model of experimental autoimmune keratoconjunctivitis sicca (KCS) induced in Lewis rat by the autoantigen Klk1b22. Invest. Ophthalmol. Vis. Sci. 2009, 50:2245-2254.
68. Jie Y., Xu L., Wu Y.Y., Jonas J.B. Prevalence of dry eye among adult Chinese in the Beijing Eye Study. Eye 2009, 23:688-693.
69. Jin Y., Shen L., Chong E.M., Hamrah P., Zhang Q., Chen L., Dana M.R. The chemokine receptor CCR7 mediates corneal antigen-presenting cell trafficking. Mol. Vis. 2007, 13:626-634.
70. Jin Y., Arita M., Zhang Q., Saban D.R., Chauhan S.K., Chiang N., Serhan C.N., Dana R. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 2009, 50:4743-4752.
71. Jin Y., Chauhan S.K., Saban D.R., Dana R. Role of CCR7 in facilitating direct allosensitization and regulatory T-cell function in high-risk corneal transplantation. Invest. Ophthalmol. Vis. Sci. 2010, 51:816-821.
72. Kang M.H., Kim M.K., Lee H.J., Lee H.I., Wee W.R., Lee J.H. Interleukin-17 in various ocular surface inflammatory diseases. J. Korean Med. Sci. 2011, 26:938-944.
73. Kaswan R.l., Salisbury M.A., Ward D.A. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch. Ophthalmol. 1989, 107:1210-1216.
74. Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007, 19:24-32.
75. Kennedy M.C., Rosenbaum J.T., Brown J., Planck S.R., Huang X., Armstrong C.A., Ansel J.C. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J. Clin. Invest. 1995, 95:82-88.
76. Kong L., Robinson C.P., Peck A.B., et al. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin. Exp. Rheumatol. 1998, 16:675-681.
77. Krenzer K.L., Dana M.R., Ullman M.D., Cermak J.M., Tolls D.B., Evans J.E., Sullivan D.A. Effect of androgen deficiency on the human meibomian gland and ocular surface. J. Clin. Endocrinol. Metab. 2000, 85:4874-4882.
78. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 2005, 6:1219-1227.
79. Küchle M., Cursiefen C., Nguyen N.X., Langenbucher A., Seitz B., Wenkel H., Martus P., Naumann G.O. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes. Arch. Clin. Exp. Ophthalmol. 2002, 240:580-584.
80. Kunert K.S., Tisdale A.S., Stern M.E., Smith J.A., Gipson I.K. Analysis of topical cyclosporine A treatment of patients with dry eye syndrome. Arch. Ophthalmol. 2000, 118:1489-1496.
81. Kuzin I.I., Snyder J.E., Ugine G.D., Wu D., Lee S., Bushnell T., Insel R.A., Young F.M., Bottaro A. Tetracyclines inhibit activated B cell function. Int. Immunol. 2001, 13:921-931.
82. Lam H., Bleiden L., de Paiva C.S., Farley W., Stern M.E., Pflugfelder S.C. Tear cytokine profiles in dysfunctional tear syndrome. Am. J. Ophthalmol. 2009, 147:198-205.
83. Lang Y., Lang N., Ben-Ami M., Garzozi H. The effects of hormone replacement therapy (HRT) on the human eye. Harefuah 2002, 141:287-291.
84. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
85. Levings M.K., Allan S., d'Hennezel E., Piccirillo C.A. Functional dynamics of naturally occurring regulatory T cells in health and autoimmunity. Adv. Immunol. 2006, 92:119-155.
86. Liden J., Rafter I., Truss M., Gustafsson J.A., Okret S. Glucocorticoid effects on NF-kappa B binding in the transcription of the ICAM-1 gene. Biochem. Biophys. Res. Commun. 2000, 273:1008-1014.
87. Li D.Q., Lokeshwar B.L., Solomon A., Monroy D., Ji Z., Pflugfelder S.C. Regulation of MMP-9 production by human corneal epithelial cells. Exp. Eye Res. 2001, 73:449-459.
88. Li D.Q., Shang T.Y., Kim H.S., Solomon A., Lokeshwar B.L., Pflugfelder S.C. Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2003, 44:2928-2936.
89. Li D.Q., Zhou N., Zhang L., Ma P., Pflugfelder S.C. Azithromycin suppresses Zymosan-induced production of pro-inflammatory mediators by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 2010, 51:5623-5629.
90. Liu Y., Hamrah P., Zhang Q., Taylor A.W., Dana M.R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J. Exp. Med. 2002, 195:259-268.
91. Loteprednol Etabonate US Uveitis Study Group Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am. J. Ophthalmol. 1999, 127:537-544.
92. Lu P., Li L., Liu G., Zhang X., Mukaida N. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. Invest. Ophthalmol. Vis. Sci. 2009, 50:4761-4768.
93. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-449.
94. Ma X., Li J. Corneal neovascularization suppressed by TIMP2 released from human amniotic membranes. Yan Ke Xue Bao 2005, 21:56-61.
95. Mantopoulos D., Cruzat A., Hamrah P. In vivo imaging of corneal inflammation: new tools for clinical practice and research. Semin. Ophthalmol. 2010, 25:178-185.
96. Marsh P., Pflugfelder S.C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. Ophthalmology 1999, 106:811-816.
97. Massingale M.L., Li X., Vallabhajosyula M., Chen D., Wei Y., Asbell P.A. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009, 28:1023-1027.
98. Mathers W.D., Lane J.A., Zimmerman M.B. Tear film changes associated with normal aging. Cornea 1996, 15:229-234.
99. Mazan M.M., Hughes C.C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 2002, 169:3581-3588.
100. Mills K.H. Induction, function and regulation of IL-17-producing T cells. Eur. J. Immunol. 2008, 38:2636-2649.
101. Miljanović B., Dana R., Sullivan D.A., Schaumberg D.A. Impact of dry eye syndrome on vision-related quality of life. Am. J. Ophthalmol. 2007, 143:409-415.
102. Mohammed I., Abedin A., Tsintzas K., Abedin S.A., Otri A.M., Hopkinson A., Mathew M., Dua H.S. Increased expression of hepcidin and toll-like receptors 8 and 10 in viral keratitis. Cornea 2011, 30:899-904.
103. Moss S.E., Klein R., Klein B.E.K. Prevalence and risk factors for dry eye syndrome. Arch. Ophthalmol. 2000, 118:1264-1268.
104. Motterle L., Diebold Y., Enríquez de Salamanca A., Saez V., Garcia-Vazquez C., Stern M.E., Calonge M., Leonardi A. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch. Ophthalmol. 2006, 124:462-468.
105. Niederkorn J.Y., Stern M.E., Pflugfelder S.C., De Paiva C.S., Corrales R.M., Gao J., Siemasko K. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. J. Immunol. 2006, 176:3950-3957.
106. no authors listed The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul. Surf. 2007, 5:75-92.
107. Okanobo, A., Chauhan, S.K., Dastjerdi, M., Kodati, S., Dana, R., Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am. J. Ophthalmol., in press.
108. Patel S., Farrell J.C. Age related changes in precorneal tear film stability. Optom. Vis. Sci. 1989, 66:175-178.
109. Pflugfelder S.C., Maskin S.L., Anderson B., Chodosh J., Holland E.J., De Paiva C.S., Bartels S.P., Micuda T., Proskin H.M., Vogel R. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol. 2004, 138:444-457.
110. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 2004, 16:81-88.
111. Pisella P.J., Brignole F., Debbasch C., Lozato P.A., Creuzot-Garcher C., Bara J., Saiag P., Warnet J.M., Baudouin C. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. Ophthalmology 2000, 107:1841-1849.
112. Poggio E.C., Abelson M.B. Complications and symptoms with disposable daily wear contact lenses and conventional soft daily wear contact lenses. CLAO J. 1993, 19:95-102.
113. Prabhasawat P., Tseng S.C.G. Frequent association of delayed tear clearance in ocular irritation. Br. J. Ophthalmol. 1998, 82:666-675.
114. Rao S., Rao R. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006, 25:674-678.
115. Rashid S., Jin Y., Ecoiffier T., Barabino S., Schaumberg D.A., Dana M.R. Topical omega-3 and omega-6 Fatty acids for treatment of dry eye. Arch. Ophthalmol. 2008, 126:219-225.
116. Redfern R.L., McDermott A.M. Toll-like receptors in ocular surface disease. Exp. Eye Res. 2010, 90:679-687.
117. Reinoso R., Calonge M., Castellanos E., Martino M., Fernández I., Stern M.E., Corell A. Differential cell proliferation, apoptosis, and immune response in healthy and evaporative-type dry eye conjunctival epithelia. Invest. Ophthalmol. Vis. Sci. 2011, 52:4819-4828.
118. Rose C.M., Qian L., Hakim L., Wang Y., Jerdeva G.Y., Marchelletta R., Nakamura T., Hamm-Alvarez S.F., Mircheff A.K. Accumulation of catalytically active proteases in lacrimal gland acinar cell endosomes during chronic ex vivo muscarinic receptor stimulation. Scand. J. Immunol. 2005, 61:36-50.
119. Rosen J., Miner J.N. The search for safer glucocorticoid receptor ligands. Endocr. Rev. 2005, 26:452-464.
120. Rosenberg E.S., Asbell P.A. Essential fatty acids in the treatment of dry eye. Ocul. Surf. 2010, 8:18-28.
121. Ryan M.E., Usman A., Ramamurthy N.S., Golub L.M., Greenwald R.A. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr. Med. Chem. 2001, 8:305-316.
122. Sack R.A., Conradi L., Krumholz D., Beaton A., Sathe S., Morris C. Membrane array characterization of 80 chemokines, cytokines, and growth factors in open- and closed-eye tears: angiogenin and other defense system constituents. Invest. Ophthalmol. Vis. Sci. 2005, 46:1228-1238.
123. Sacks E.H., Wieczorek R., Jakobiec F.A., Knowles D.M. Lymphocytic subpopulations in the normal human conjunctiva. A monoclonal antibody study. Ophthalmology 1986, 93:1276-1283.
124. Sadrai Z., Hajrasouliha A.R., Chauhan S., Saban D.R., Dastjerdi M.H., Dana R. Effect of topical azithromycin on corneal innate immune responses. Invest. Ophthalmol. Vis. Sci. 2011, 52:2525-2531.
125. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 2010, 10:490-500.
126. Sainz de la Maza Serra M., Simon Castellvi C., Kabbani O. Nonpreserved topical steroids and lacrimal punctual occlusion for severe keratoconjunctivitis sicca. Arch. Soc. Esp. Ophthalmol. 2000, 75:751-756.
127. Salib G., McDonald M., Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J. Cataract Refract. Surg. 2006, 32:772-778.
128. Sall K., Stevenson O.D., Mundorf T.K., Reis B.L., the CsA phase 3 study group Two multicenter, randomized studies of the efficacy and safety of CsA ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000, 107:631-639.
129. Samtani S., Amaral J., Campos M.M., Fariss R.N., Becerra S.P. Doxycycline - mediated inhibition of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2009, 50:5098-5106.
130. Schaumberg D.A., Buring J.E., Sullivan D.A., Dana M.R. Hormone replacement therapy and dry eye syndrome. JAMA 2001, 286:2114-2119.
131. Schaumberg D.A., Sullivan D.A., Dana M.R. Epidemiology of dry eye syndrome. Adv. Exp. Med. Biol. 2002, 506:989-998.
132. Schaumberg D.A., Sullivan D.A., Buring J.E., Dana M.R. Prevalence of dry eye syndrome among US women. Am. J. Ophthalmol. 2003, 136:318-326.
133. Schaumberg D.A., Dana R., Buring J.E., Sullivan D.A. Prevalence of dry eye disease among US men: estimates from the Physicians' Health studies. Arch. Ophthalmol. 2009, 127:763-768.
134. Scott G., Yiu S.C., Wasilewski D., Song J., Smith R.E. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am. J. Ophthalmol. 2005, 139:1109-1110.
135. Seo M.J., Kim J.M., Lee M.J., Sohn Y.S., Kang K.K., Yoo M. The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model. Curr. Eye Res. 2010, 35:165-175.
136. Shen L., Barabino S., Taylor A.W., Dana M.R. Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch. Ophthalmol. 2007, 125:908-915.
137. Shen L., Jin Y., Freeman G.J., Sharpe A.H., Dana M.R. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J. Immunol. 2007, 179:3672-3679.
138. Shevach E.M. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006, 25:195-201.
139. Shi F.D., Wang H.B., Li H., Hong S., Taniguchi M., Link H., Van Kaer L., Ljunggren H.G. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 2000, 1:245-251.
140. Shine W.E., McCulley J.P., Pandya A.G. Minocycline effect on Meibomian gland lipids in meibomianitis patients. Exp. Eye Res. 2003, 76:417-420.
141. Shlopov B.V., Smith G.N., Cole A.A., Hasty K.A. Differential patterns of response to doxycycline and transforming growth factor beta1 in the downregulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum. 1999, 42:719-727.
142. + regulatory T Cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation. Invest. Ophthalmol. Vis. Sci. 2008, 49:5434-5440.
143. Smith G.N., Mickler E.A., Hasty K.A., Brandt K.D. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999, 42:1140-1146.
144. + Treg-mediated suppression. Trends Immunol. 2008, 29:337-342.
145. Sneddon I.B. A clinical trial of tetracycline in rosacea. Br. J. Dermatol. 1966, 78:649-652.
146. Solomon A., Rosenblatt M., Li D.Q., Monroy D., Ji Z., Lokeshwar B.L., Pflugfelder S.C. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest. Ophthalmol. Vis. Sci. 2000, 41:2544-2557.
147. Solomon A., Dursun D., Liu Z., Xie Y., Macri A., Pflugfelder S.C. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest. Ophthalmol. Vis. Sci. 2001, 42:2283-2292.
148. Stern M.E., Beuerman R.W., Fox R.I., Gao J., Mircheff A.K., Pflugfelder S.C. The pathology of dry eye; the interaction between the ocular surface and lacrimal glands. Cornea 1998, 17:584-589.
149. Stern M.E., Gao J., Schwalb T.A., Ngo M., Tieu D.D., Chan C.C., Reis B.L., Whitcup S.M., Thompson D., Smith J.A. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest. Ophthalmol. Vis. Sci. 2002, 43:2609-2614.
150. Stern M.E., Schaumburg C.S., Dana R., Calonge M., Niederkorn J.Y., Pflugfelder S.C. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 2010, 3:425-442.
151. Stone D.U., Chodosh J. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature. Cornea 2004, 23:106-109.
152. Streilein J.W. New thoughts on the immunology of corneal transplantation. Eye (Lond) 2003, 17:943-948.
153. Streilein J.W., Niederkorn J.Y. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J. Immunol. 1985, 134:1381-1387.
154. Strong B., Farley W., Stern M.E., Pflugfelder S.C. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005, 24:80-85.
155. + T helper 1 cells by a contact-dependent mechanism. Invest. Ophthalmol. Vis. Sci. 2009, 50:263-272.
156. Sullivan D.A., Sullivan B.D., Evans J.E., Schirra F., Yamagami H., Liu M., Richards S.M., Suzuki T., Schaumberg D.A., Sullivan R.M., Dana M.R. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann. N. Y. Acad. Sci. 2002, 966:211-222.
157. Sullivan B.D., Evans J.E., Dana M.R., Sullivan D.A. Influence of aging on the polar and neutral lipid profiles in human Meibomian gland secretions. Arch. Ophthalmol. 2006, 124:286-292.
158. Sullivan D.A., Jensen R.V., Suzuki T., Richards S.M. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands?. Mol. Vis. 2009, 15:1553-1572.
159. Suzuki T., Sullivan D.A. Estrogen stimulation of proinflammatory
160. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 2002, 169:2461-2465.
161. Szliter E.A., Lighvani S., Barrett R.P., Hazlett L.D. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J. Immunol. 2007, 178:1105-1114.
162. Ta C.N., Shine W.E., McCulley J.P., Pandya A., Trattler W., Norbury J.W. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003, 22:545-548.
163. Thoft R.A., Friend J. Biochemical transformation of regenerating ocular surface epithelium. Invest. Ophthalmol. Vis. Sci. 1977, 16:14-20.
164. Turner K., Pflugfelder S.C., Ji Z., Feuer W.J., Stern M., Reis B.L. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000, 19:494-496.
165. Uncu G., Avci R., Uncu Y., Kaymaz C., Develioĝlu O. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol. Endocrinol. 2006, 22:501-550.
166. Viau S., Maire M.A., Pasquis B., Grégoire S., Acar N., Bron A.M., Bretillon L., Creuzot-Garcher C.P., Joffre C. Efficacy of a 2-month dietary supplementation with polyunsaturated fatty acids in dry eye induced by scopolamine in a rat model. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1039-1050.
167. Villani E., Galimberti D., Viola F., Mapelli C., Ratiglia R. The cornea in Sjogren's syndrome: an in vivo confocal study. Invest. Ophthalmol. Vis. Sci. 2007, 48:2017-2022.
168. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 2007, 25:821-852.
169. Wilbanks G.A., Streilein J.W. Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology 1990, 71:383-389.
170. Winkler-Pickett R., Young H.A., Cherry J.M., Diehl J., Wine J., Back T., Bere W.E., Mason A.T., Ortaldo J.R. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: alteration of primary adaptive responses. J. Immunol. 2008, 180:4495-4506.
171. Yamagami S., Hamrah P., Zhang Q., Liu Y., Huq S., Dana M.R. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Mol. Vis. 2005, 11:632-640.
172. Yeh S., Song X.J., Farley W., Li D.Q., Stern M.E., Pflugfelder S.C. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest. Ophthalmol. Vis. Sci. 2003, 44(1):124-129.
173. Yoon K.C., De Paiva C.S., Qi H., Chen Z., Farley W.J., Li D.Q., Pflugfelder S.C. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest. Ophthalmol. Vis. Sci. 2007, 48:2561-2569.
174. Yoon K.C., Park C.S., You I.C., Choi H.J., Lee K.H., Im S.K., Park H.Y., Pflugfelder S.C. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest. Ophthalmol. Vis. Sci. 2010, 51:643-650.
175. Yoshida T., Tanaka M., Sotomatsu A., Okamoto K. Effect of methylprednisolone pulse therapy on superoxide production of neutrophils. Neurol. Res. 1999, 21:509-512.
176. Yüksel B., Bozdag B., Acar M., Topaloglu E. Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur. J. Ophthalmol. 2010, 20:675-679.
177. Zylberberg C., Seamon V., Ponomareva O., Vellala K., Deighan M., Azzarolo A.M. Estrogen up-regulation of metalloproteinase-2 and -9 expression in rabbit lacrimal glands. Exp. Eye Res. 2007, 84:960-972.